GE shares jump again as Wall Street loves Danaher deal: Stock no longer has 'downside risk' - Recent News from USA
A GE Healthcare Ltd. BioProcess machine stands on display during the International Pharmaceutical Expo (Interphex) in New York.

GE shares jump again as Wall Street loves Danaher deal: Stock no longer has 'downside risk'

UBS analyst Peter Lennox-King believes this new source of cash for GE, as well as the benefits, is a boon for the company.

“The sale of GE BioPharma to Danaher effectively puts the leverage question to bed,” Lennox-King said.

Deutsche Bank analyst Nicole DeBlase was the odd one out among the group, however, despite raising the firm’s price target on GE to $11 a share.

“GE is left with the less attractive parts of the Healthcare business,” DeBlase said of the deal.

Here’s what major Wall Street analysts said about GE’s deal.

Source link

Posts created 2651

Related Posts

Begin typing your search term above and press enter to search. Press ESC to cancel.

Back To Top